Insider buying last 90 days
No open-market insider purchases were filed for IOSP in the last 90 days.
From Form 4 filings, dated to when each was filed.
Oct 12 close
Innospec's week centers on its scheduled Q3 2026 earnings release, confirmed for 3 November with a conference call the following day hosted by CEO Patrick S. Williams and CFO Ian Cleminson. Coverage also revisited the Q2 2026 results, with revenue of $491.4 million, up 12% year-over-year, and adjusted EPS that exceeded consensus estimates, alongside double-digit growth across segments and Performance Chemicals operating income up 15%. Argus raised its price target on the stock to $103.00. Separately, a passive holder disclosed a 4.7% stake of 1,161,421 shares via a Schedule 13G filing.
The stock closed at $95.66, sitting above both its 50-day average of $94.17 and its 200-day average of $82.97, with the shorter average above the longer one, reflecting a supportive trend. Shares have gained 2.6% over one month, 17.2% over three months, and 25.4% over the past year, trading within a 52-week range of $65.51 to $100.48. The GekkoIndex reads 56, placing it in the Neutral zone, while price sits about 1% below Gekko Fair Value of $96.67.
Earnings arrive on 3 November, 21 days out, falling inside a typical 20-trading-day holding window, with the last report producing a 7.6% reaction and six beats in eight quarters. No insider, Congress, or options activity appears in their respective windows. Seasonally, the next 20 trading days from this point have averaged an 8.5% gain over 5 years, positive in 4 of them, a pattern worth noting alongside the upcoming report.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Innospec scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
Above 50 and 200-day
Close $95.66 is above the 50-day ($94.17) and 200-day ($82.97) averages, and the 50-day is above the 200-day.
See the chart56, Neutral
Reading 56 is in the Neutral zone.
See the GekkoIndex1.0% below
Price is within 5% of Gekko Fair Value (1% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 22 days
Reports on Nov 3, 2026, 22 days away — inside a typical 20-trading-day hold.
See earnings+8.5% on average
From this point in the calendar, the next 20 trading days averaged +8.5% over 5 years, rising in 4 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Innospec closed at $95.66 on Oct 12, 2026, +25.4% over the past year, inside a 52-week range of $65.51 to $100.48.
Use the left and right arrow keys to read daily values.
Put IOSP on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Innospec makes specialty chemicals that go into fuel, personal care, agriculture, and oil extraction work. Its additives help engines run in cars, ships, and planes, and they also show up in generators and heating oil setups. Buyers span fuel makers, industrial firms, and companies in oil and gas.
The company runs three main lines of business. One, Fuel Specialties, builds additive blends for engines and fuel systems. Another, Performance Chemicals, supplies formulations for personal care, household goods, crop chemicals, and metal recovery work. The third, Oilfield Services, focuses on chemicals that support fracturing, well stimulation, and completion, along with products used in extraction and drilling fluid management. Its customer base includes oil and gas producers, refiners, fuel distributors, personal and home care brands, agrochemical formulators, and other industrial users.
The company began in 1938 under the name Octel Corp, later taking the Innospec name in 2006. It runs out of Englewood, Colorado, and does business across the United States, the rest of North America, the UK, continental Europe, and other markets abroad. Its stock trades on the NASDAQ under the ticker IOSP.
Innospec’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 56, in the Neutral zone, up 5.4 points over five sessions.
Up 5.4 points over five sessions.
Reading for Oct 12, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 59 | +1.0% | +3.4% | ||
| Accumulation | 226 | −0.3% | −0.5% | ||
| Neutral (current zone) | 354 | 0.0% | −0.5% | ||
| Distribution | 40 | −0.9% | −4.3% | ||
| Selling | 3 | Too few readings yet | |||
Average IOSP share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Innospec trades 1.0% below Gekko Fair Value of $96.67, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Innospec shares are worth, recalculated every trading day.
$96.67
Gekko Fair Value, Oct 10, 2026
1.0% below fair value · About fair value
At the end of Aug 2026 the price was 5.1% below the estimate.
No open-market insider purchases were filed for Innospec, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for IOSP in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in IOSP were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Innospec has been buying back its own shares.
From company filings.
Innospec reports on Nov 3, 2026 (22 days away), and beat the EPS estimate in 6 of its last 8 reports.
Nov 3, 2026
22 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | $1.27 est $1.05 | $491.4M est $457.2M | +7.6% |
| May 7, 2026 | $1.05 est $1.32 | $453.2M est $432.1M | +3.7% |
| Feb 17, 2026 | $1.50 est $1.26 | $455.6M est $460.9M | −0.3% |
| Nov 4, 2025 | $1.12 est $1.03 | $441.9M est $460.9M | +0.5% |
| Aug 5, 2025 | $1.26 est $1.17 | $439.7M est $450.0M | −1.4% |
| May 8, 2025 | $1.42 est $1.40 | $440.8M est $467.6M | −1.7% |
| Feb 18, 2025 | $1.41 est $1.36 | $466.8M est $447.4M | −5.5% |
| Nov 5, 2024 | $1.35 est $1.35 | $443.4M est $454.9M | +14.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Innospec is $101.00, +5.6% from the last close, from 1 firm rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 1 firm.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Aug 6 | Seaport Global | $110 | +15.0% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Oct 10, Innospec averaged +8.5% across the last 5 years, rising in 4 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.3% | 4 of 5 |
| Next 10 trading days | +1.8% | 3 of 5 |
| Next 15 trading days | +3.5% | 2 of 5 |
| Next 20 trading days | +8.5% | 4 of 5 |
| Next 30 trading days | +8.3% | 4 of 5 |
For scale, IOSP’s typical 20-trading-day move in either direction is about 5.1%.
Innospec’s market cap is $2.36B, with a P/E ratio of 19.9 and revenue of $1.84B over the last twelve months.
Coverage of Innospec this week reads neutral: 5 positive, 10 neutral and 0 negative headlines.
Innospec’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| DDDuPont de Nemours | Accumulation | 5.8% above |
| SOLSSolstice Advanced Materials | Neutral | 44.8% below |
| ESIElement Solutions | Neutral | 10.1% above |
| PRMPerimeter Solutions | Accumulation | 24.0% below |
| AVNTAvient | Buying | 36.4% below |
| NGVTIngevity | Accumulation | 12.1% below |
A peer links to its own page where one exists.
Innospec’s market cap is $2.36B at the Oct 12, 2026 close of $95.66, with 24.63M shares outstanding. The shares trade on a P/E ratio of 19.9.
The consensus analyst 12-month price target for Innospec is $101.00, +5.6% from the last close. Of the 1 firm that rated the stock in the last 90 days, 1 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Innospec is about fair value: the Oct 12, 2026 close of $95.66 is 1.0% below Gekko Fair Value of $96.67. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Innospec is expected to report on Nov 3, 2026 (22 days away). Analysts expect earnings of $1.27 per share on revenue of $478.3M. Innospec beat the earnings estimate in 6 of its last 8 reports, moving 4.4% on average across the report.
Innospec’s 52-week high is $100.48 and its 52-week low is $65.51; it closed at $95.66 on Oct 12, 2026, +25.4% over the past year. Over the last five years the shares peaked at $133.71 on May 10, 2024.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and seasonality), 2 as mixed (gekkoindex and fair value) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.